Celldex Therapeutics Highlights Barzolvolimab Phase 3 Wins, New Trials at TD Cowen Conference [Yahoo! Finance]
Celldex Therapeutics, Inc. (CLDX)
Last celldex therapeutics, inc. earnings: 11/12 08:01 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.celldex.com
Company Research
Source: Yahoo! Finance
ahead of schedule and are 90% powered to detect a 10-point improvement in UAS7 with a 12-week primary endpoint, including analysis in omalizumab-refractory patients. The company has started a Phase 3 single-dose study in CIndU (~240 patients) and expects multiple dermatology readouts later this year — notably prurigo nodularis (n=140) and atopic dermatitis (n=131) — while bispecific program CDX-622 has entered Part 2 with IV and subcutaneous data expected this summer. Celldex plans a commercial launch using an in-office pre-filled syringe with a self-injectable auto-injector about a year later, is considering a premium pricing strategy versus peers, and is running safety work including a male fertility (sperm) study to support a planned BLA. Interested in Celldex Therapeutics, Inc.? Here are five stocks we like better. Executives from Celldex Therapeutics (NASDAQ:CLDX) outlined a busy year of clinical and development milestones at the TD Cowen Healthcare Conference, highlighti
Show less
Read more
Impact Snapshot
Event Time:
CLDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLDX alerts
High impacting Celldex Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CLDX
News
- A Look At Celldex Therapeutics (CLDX) Valuation After Recent Share Price Weakness And Strong 1 Year Return [Yahoo! Finance]Yahoo! Finance
- Celldex Therapeutics Touts Barzolvolimab Phase III CSU Momentum, Lays Out 2026 Data Catalysts [Yahoo! Finance]Yahoo! Finance
- Celldex Therapeutics (CLDX) had its price target raised by The Goldman Sachs Group, Inc. from $30.00 to $34.00. They now have a "neutral" rating on the stock.MarketBeat
- Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-DiseaseAcquire Media Monitor
- Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-DiseaseGlobeNewswire
CLDX
Earnings
- 2/25/26 - Miss
CLDX
Sec Filings
- 3/10/26 - Form SCHEDULE
- 2/25/26 - Form 10-K
- 2/25/26 - Form 8-K
- CLDX's page on the SEC website